Popular Articles
Burdock Root

The Fitness Revolution - Launch Of The UK's First Dedicated Health And Fitness Channel
The fight against obesity has stepped up a gear with the
generic viagra online
Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (Mesalamine) Delayed-Release Tablets For Moderately Active Ulcerative Colitis
Procter & Gamble Pharmaceuticals (P&GP) announced the availability of Asacol HD (mesalamine) delayed-release tablets, which are indicated for the treatment of moderately active ulcerative colitis (UC), a form of inflammatory bowel disease. UC involves inflammation of the lining of the colon and rectum and is typically characterized by flares followed by periods of remission. Moderately active UC is characterized by tougher symptoms than mildly active UC. Asacol HD is proven to help treat these tougher flares of moderately active UC. Asacol HD was approved by the U.S. Food and Drug Administration (FDA) based on evaluations from the ASCEND studies [Assessing the Safety and Clinical Efficacy of a New Dose of 5-ASA (4.8 g/day 800 mg tablet)].
News of the day
HIV Antibody Tests Unreliable For Early Infections In Teens
A previously healthy teenager shows up at the doctor"s office with a sore throat, fever, aches and general malaise. Routine blood tests are normal, an HIV test comes back negative, and the pediatrician sends the patient home with a diagnosis of acute viral infection.
Endocrinology

UQ Scientist's Outstanding Pain Management Research Recognised

A UQ Science researcher has received a prestigious honorary fellowship for her long-time work into understanding the underlying mechanisms of pain. Professor Maree Smith has been awarded the Honorary Fellowship by the Australian and New Zealand College of Anaesthetists" Faculty of Pain Medicine. The Faculty of Pain Medicine admits distinguished persons who have made a notable contribution to the advancement of the science and practice of pain medicine, but are not practising pain medicine in Australia or New Zealand. Executive Director of UQ"s Centre for Integrated Preclinical Drug Development and its commercial arm, TetraQ, Professor Smith said she was very surprised to be honoured. "When I got the letter and opened it, I just thought "wow", I didn"t even know they did this," she said. "I feel really flattered and honoured, my research team and I have been working away in the field for about two decades now because that"s what you need to do in order to make a difference, I never expected to get recognised for it." Pain medicine is a multidisciplinary field of specialist medical practice that has matured relatively recently. The field recognises the management of severe pain problems requires the skills of more than one medical discipline. Professor Smith has specialist expertise in pre-clinical drug development as well as the mechanistic basis of pain and its pharmacological management. As TetraQ CEO, a leading Australian preclinical drug development contract research organisation based at UQ, Professor Smith is in a unique position to further pain medicine. "At TetraQ we sit in the translational research space," she said. "We assist universities and small biotech and pharmaceutical companies in getting potential drugs from the laboratory bench to the pharmacy. "We perform the preclinical drug trials, showing these drugs are efficacious - they do what the company says they do - and that they are safe to go on to human trials." This isn"t the first award Professor Smith has received for her contributions to science, in 2008 she received the Women in Technology Biotech Outstanding Achievement Award. And in 2003, Professor Smith was awarded a "Trailblazer Challenge" award by UniQuest, for developing new treatments for the pain caused by sciatica and other forms of nerve damage. The FPM is the body responsible for training, education and standards for Pain Medicine in Australia and New Zealand. The University of Queensland


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):